drugset / Trial / NCT00412997

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

NCT00412997

Phase 1 Completed 14 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma

Timeline

Start
2006-11
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule Oral